Longer Deep Molecular Response for Chronic MyeloidLeukemia Patients before TKI Discontinuation: Evidencefrom the AST- Argentina Stop Trial

BIANCHINI M

Congreso; ESH (EUROPEAN SCHOOL OF HAEMATOLOGY); 2021

Background: Treatment-free remission (TFR) is an emergingtreatment goal for chronic myeloid leukemia (CML) patients thatachieve deep molecular response (DMR). The AST study guaranteesadequate TFR molecular monitoring in Argentina and investigatesprognostic biomarkers to better identify patients able to sustain TFR.Objectives: To estimate the rate of treatment-free remission (TFR) inCML-CP patients with sustained MR 4.0 and to investigate biomarkersfor TFR prediction by analyzing clinical factors and the phenotype ofNK cells.Methods: AST- Argentina Stop Trial recruited CML-CP patients underTKI treatment for at least ≥ 4 years, sustained MR4.0 for ≥ 2 years,confirmed typical BCR-ABL1 transcripts b3a2 and/or b2a2 and aged >18 years.Molecular tests were performed monthly the first 6 months, every 2months until month 12, and every 3 months until month 24. TKI wasrestarted at loss major molecular response (MMR). I